Revolution Medicines wins FDA approval for pancreatic cancer drug; analysts forecast $11.5B peak sales

By Eric Volkman, The Motley Fool Published: August 28, 2026, at 4:27 AM PDT | 5 min read

• RVMD: -6.00%
• NVDA: -4.57%

Well, that sure was quick.

Within weeks of submitting its promising daraxonrasib to the Food and Drug Administration (FDA), Revolution Medicines (NASDAQ: RVMD) received full approval from the U.S. regulator on Wednesday. The expedited review—remarkably fast by industry standards—drew significant attention to the company and, unsurprisingly, gave the biotech's stock a substantial boost.

Daraxonrasib, now branded as Rasonque, is undoubtedly a high-potential drug. But has its success pushed the company's stock into overvalued territory?

The Breakout of a Breakthrough Drug

Rasonque, administered once daily as a pill, was approved to treat metastatic pancreatic cancer in adults who have either received prior systemic therapy or are ineligible for combination therapy.

The drug represents a new class of cancer treatment. It works by blocking several forms of the RAS protein—a sort of on-off switch that regulates cell growth—using a novel "molecular glue" mechanism.

Pancreatic cancer is notoriously difficult to treat. As such, Rasonque qualified for the Commissioner's National Priority Voucher (CNPV) program. Launched last year, this initiative aims to reduce the FDA's typical drug approval timeline from ten months to one year down to just weeks. Only a limited number of vouchers are available under the program; Revolution's then-developmental treatment received one shortly after the company filed its application.

In the press release announcing the FDA's approval, CEO Mark Goldsmith stated:

"Rasonque is a monumental step forward for patients with pancreatic cancer and for the oncology field."

He added:

"This approval further validates our bold RAS(ON) inhibitor strategy that includes multi-selective and mutant-selective approaches targeting a major driver of pancreatic cancer and multiple other cancers."

Success in the Lab

Revolution first caught the attention of many investors and healthcare professionals in April, when the biotech presented Phase 3 data for the drug. The results demonstrated statistically significant and clinically meaningful improvements across all primary and secondary endpoints. Rasonque also compared favorably with traditional chemotherapy and was well tolerated, with a manageable safety and quality-of-life profile.

Any drug performing that well in a late-stage trial will attract the right kind of attention. What compounded this for Revolution is that the drug treats a form of cancer—a high-demand market segment—and does so in a novel and clearly efficacious way.

From that April readout to the present, Revolution's stock has largely been on a rocket ride. Zooming out, the stock has risen 178% year to date, compared to less than 13% for the broader market.